WO2007085958A3 - Diagnosis, prognosis and screening for medicaments for treatment of myeloproliferative disorders using receptor protein tyrosine-phosphatase gamma (ptprg) as biomarker - Google Patents

Diagnosis, prognosis and screening for medicaments for treatment of myeloproliferative disorders using receptor protein tyrosine-phosphatase gamma (ptprg) as biomarker Download PDF

Info

Publication number
WO2007085958A3
WO2007085958A3 PCT/IB2007/000218 IB2007000218W WO2007085958A3 WO 2007085958 A3 WO2007085958 A3 WO 2007085958A3 IB 2007000218 W IB2007000218 W IB 2007000218W WO 2007085958 A3 WO2007085958 A3 WO 2007085958A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
ptprg
prognosis
receptor protein
protein tyrosine
Prior art date
Application number
PCT/IB2007/000218
Other languages
French (fr)
Other versions
WO2007085958A2 (en
Inventor
Claudio Sorio
Original Assignee
Consorzio Per Gli Studi Uni In
Claudio Sorio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consorzio Per Gli Studi Uni In, Claudio Sorio filed Critical Consorzio Per Gli Studi Uni In
Priority to EP07700532A priority Critical patent/EP1987157A2/en
Publication of WO2007085958A2 publication Critical patent/WO2007085958A2/en
Publication of WO2007085958A3 publication Critical patent/WO2007085958A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for the diagnosis and/or prognosis of myeloproliferative diseases by means of identification of the expression of the receptor protein tyrosine-phosphatase gamma (PTPRG). A method based on the use of antibodies for the isolation of blood cells expressing this marker. This method is applied preferentially, but not exclusively, to chronic myeloid leukemia and essential thrombocythemia. A molecular marker and a kit for the diagnosis of these diseases.
PCT/IB2007/000218 2006-01-24 2007-01-22 Diagnosis, prognosis and screening for medicaments for treatment of myeloproliferative disorders using receptor protein tyrosine-phosphatase gamma (ptprg) as biomarker WO2007085958A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07700532A EP1987157A2 (en) 2006-01-24 2007-01-22 Diagnosis, prognosis and screening for medicaments for treatment of myeloproliferative disorders using receptor protein tyrosine-phosphatase gamma (ptprg) as biomarker

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITVI20060029 ITVI20060029A1 (en) 2006-01-24 2006-01-24 METHOD FOR DIAGNOSTICS OF MYELOPROLIFERATIVE DISEASES
ITVI2006A000029 2006-01-24

Publications (2)

Publication Number Publication Date
WO2007085958A2 WO2007085958A2 (en) 2007-08-02
WO2007085958A3 true WO2007085958A3 (en) 2008-02-14

Family

ID=38190577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/000218 WO2007085958A2 (en) 2006-01-24 2007-01-22 Diagnosis, prognosis and screening for medicaments for treatment of myeloproliferative disorders using receptor protein tyrosine-phosphatase gamma (ptprg) as biomarker

Country Status (3)

Country Link
EP (1) EP1987157A2 (en)
IT (1) ITVI20060029A1 (en)
WO (1) WO2007085958A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053149A1 (en) * 2007-12-28 2011-03-03 Judith Mary Boer Methylation detection in the genomic region of a receptor proteintyrosine phosphatase gamma gene for detection and/or diagnosis of a tumour
WO2011044162A1 (en) * 2009-10-06 2011-04-14 Shire Human Genetic Therapies Assays for agents affecting megakaryocyte development
CN103076453B (en) * 2012-12-24 2015-04-15 何以丰 P16 immune cell chemical reagent kit and polypeptide sequence in preparing same
EP3250687A4 (en) * 2015-01-29 2018-06-20 Leuvas Therapeutics Modulators of protein tyrosine phosphatase and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001050A1 (en) * 1990-07-11 1992-01-23 New York University Novel receptor-type phosphotyrosine phosphatase
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
WO2006008633A2 (en) * 2004-07-16 2006-01-26 Consorzio Per Gli Studi Universitari In Verona Receptor protein tyrosine phosphatase gamma (ptprg) as marker for dendritic cells cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001050A1 (en) * 1990-07-11 1992-01-23 New York University Novel receptor-type phosphotyrosine phosphatase
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
WO2006008633A2 (en) * 2004-07-16 2006-01-26 Consorzio Per Gli Studi Universitari In Verona Receptor protein tyrosine phosphatase gamma (ptprg) as marker for dendritic cells cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FREISS G ET AL: "Protein tyrosine phosphatases and breast cancer", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, BOCARATON, FL, US, vol. 52, no. 1, October 2004 (2004-10-01), pages 9 - 17, XP004560866, ISSN: 1040-8428 *
LIU SULING ET AL: "Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 23, no. 6, 12 February 2004 (2004-02-12), pages 1256 - 1262, XP002378641, ISSN: 0950-9232 *
NIEKERK VAV C C ET AL: "REDUCED EXPRESSION OF PROTEIN TYROSINE PHOSPHATASE GAMMA IN LUNG AND OVARIAN TUMORS", CANCER LETTERS, NEW YORK, NY, US, vol. 137, no. 1, 1999, pages 61 - 73, XP000952708, ISSN: 0304-3835 *
SORIO C ET AL: "CHARACTERIZATION OF THE RECEPTOR PROTEIN TYROSINE PHOSPHATASE GENE PRODUCT PTPGAMMA: BINDING AND ACTIVATION BY TRIPHOYPHORYLATED NUCLEOSIDES", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 55, no. 21, 1 November 1995 (1995-11-01), pages 4855 - 4864, XP001246586, ISSN: 0008-5472 *
SORIO C ET AL: "Receptor protein tyrosine phosphatase gamma, Ptp-gamma, regulates hematopoietic differentiation", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 90, no. 1, 1997, pages 49 - 57, XP002378640, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
ITVI20060029A1 (en) 2007-07-25
EP1987157A2 (en) 2008-11-05
WO2007085958A2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
WO2007076439A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2006085984A3 (en) Immune cell biosensors and methods of using same
NZ593964A (en) Human anti-alpha-synuclein autoantibodies
WO2007000320A3 (en) Method for diagnosing rheumatic diseases
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2005098445A3 (en) Lung cancer biomarkers
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
WO2006084272A3 (en) Methods of predicting chemotherapy responsiveness in breast cancer patients
WO2009029591A3 (en) Monoclonal antibody which binds met in formalin-fixed and paraffin-embedded tissues and related methods
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2009019370A3 (en) Apolipoprotein aii assay method for the in vitro diagnosis of colorectal cancer
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
WO2009087462A3 (en) Ephrin type-a receptor 10 protein
WO2006094014A3 (en) Methods for diagnosis and treatment of endometrial cancer
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
WO2011093675A3 (en) Biological method and system for selecting diagnostic marker for subtype of lung cancer directly from blood, and marker for diagnosis of lung cancer selected with the system
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2006121710A3 (en) Bladder cancer biomarkers and uses thereof
WO2007085958A3 (en) Diagnosis, prognosis and screening for medicaments for treatment of myeloproliferative disorders using receptor protein tyrosine-phosphatase gamma (ptprg) as biomarker
WO2007077543A3 (en) Sigma-2 receptor, method of screening of specific ligands and use of the same in diagnostic or therapeutic methods
WO2008137733A3 (en) Micellar structures, methods of making micellar structures, methods of imaging, and methods of delivering agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007700532

Country of ref document: EP